#None #Pomerantz #XOMA #Rezolute

Investor Investigation: Pomerantz Law Firm Takes Action for XOMA Investors

Pomerantz LLP has initiated an investigation related to XOMA Royalty Corporation, a firm listed on NASDAQ under the ticker symbol XOMA. This revelation has emerged following recent developments that have raised concerns about possible securities fraud and other unlawful business practices conducted by the company and some of its senior officers.

The investigation aims to ascertain whether XOMA engaged in practices that might have misled investors, especially in light of negative news released by Rezolute, Inc., which holds a partnership with XOMA for drug development. On December 11, 2025, Rezolute announced the disappointing results from a critical Phase 3 clinical trial assessing the efficacy of its drug candidate, ersodetug, intended for the treatment of congenital hyperinsulinism (HI).

The trial results were particularly troubling, revealing that the study did not meet its primary endpoint. It was supposed to demonstrate a significant reduction in weekly hypoglycemia events measured through self-monitoring blood glucose. The outcomes showed a mere 45% reduction in hypoglycemia events at the highest dose of ersodetug (10 mg/kg), which was not statistically significant compared to a 40% improvement in the placebo group. Furthermore, an evaluation of secondary endpoints reflected similarly disappointing findings: a 25% reduction in the time patients spent in hypoglycemia, again not statistically significant against a minor increase in the placebo group.

The impact on XOMA's stock was immediate and severe; shares plummeted by $7.82, representing a dramatic decrease of 22.76%, closing at $25.39 just days later on December 19, post the unfavorable news.

Pomerantz, known for its diligent work in protecting the rights of investors, especially concerning securities fraud, is reaching out to any affected investors to discuss their options. Interested parties are urged to connect with Danielle Peyton from Pomerantz, who can be contacted via email or at 646-581-9980, ext. 7980, for more details about joining the potential class action lawsuit.

Founded over 85 years ago, Pomerantz LLP is recognized as a leader in corporate and securities litigation. It has a storied history of advocating for class members impacted by fraudulent practices in financial markets. The firm has successfully recovered millions of dollars on behalf of clients, showcasing its commitment to fighting for justice.

The investigation remains ongoing, and as developments unfold, both current and former investors in XOMA Royalty Corporation are encouraged to stay abreast of updates from Pomerantz and to consider their legal options. With the firm’s extensive reach, including offices in major cities worldwide such as New York, Chicago, and Tel Aviv, they bring significant expertise to the complicated arena of securities law.

In a landscape where transparency is paramount, XOMA's board and management will be scrutinized closely to ensure investors' rights are upheld and that any potential wrongdoing is addressed swiftly and justly. As this situation evolves, affected parties should remain vigilant.